MXPA05013048A - Composiciones peptodicas farmaceuticas estabilizadas. - Google Patents
Composiciones peptodicas farmaceuticas estabilizadas.Info
- Publication number
- MXPA05013048A MXPA05013048A MXPA05013048A MXPA05013048A MXPA05013048A MX PA05013048 A MXPA05013048 A MX PA05013048A MX PA05013048 A MXPA05013048 A MX PA05013048A MX PA05013048 A MXPA05013048 A MX PA05013048A MX PA05013048 A MXPA05013048 A MX PA05013048A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide compositions
- stabilized pharmaceutical
- pharmaceutical peptide
- peptide
- stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe un metodo para incrementar la viada en anaquel de una composicion farmaceutica para la administracion parenteral, que comprende un peptido similar al glucagon, que es preparado a partir de un producto peptidico que ha sido sometido a tratamiento a un pH por arriba del pH neutro.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300819 | 2003-06-03 | ||
US47627903P | 2003-06-05 | 2003-06-05 | |
DKPA200400075 | 2004-01-19 | ||
US53852504P | 2004-01-22 | 2004-01-22 | |
PCT/DK2004/000380 WO2004105781A2 (en) | 2003-06-03 | 2004-06-03 | Stabilized pharmaceutical peptide compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05013048A true MXPA05013048A (es) | 2006-03-02 |
Family
ID=33494167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05013048A MXPA05013048A (es) | 2003-06-03 | 2004-06-03 | Composiciones peptodicas farmaceuticas estabilizadas. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1633390B1 (es) |
KR (1) | KR101293507B1 (es) |
AU (1) | AU2004243531B2 (es) |
CA (1) | CA2527743A1 (es) |
MX (1) | MXPA05013048A (es) |
PL (1) | PL1633390T3 (es) |
WO (1) | WO2004105781A2 (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1412384T3 (da) | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
KR101308912B1 (ko) | 2003-06-03 | 2013-09-23 | 노보 노르디스크 에이/에스 | 안정화된 약학적 펩티드 조성물 |
JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
KR101243648B1 (ko) | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
EP1789434B1 (en) | 2004-08-31 | 2013-11-20 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
EP1817048B1 (en) | 2004-11-12 | 2014-02-12 | Novo Nordisk A/S | Stable formulations of insulinoptropic peptides |
CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
AU2008205229B2 (en) * | 2007-01-05 | 2014-03-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
CA2707861A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
CA2702289A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
NZ589847A (en) | 2008-06-17 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
JP5753779B2 (ja) | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
EP2952202B1 (en) | 2008-06-17 | 2017-10-18 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
RS56632B1 (sr) | 2008-10-17 | 2018-03-30 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
AR074811A1 (es) | 2008-12-19 | 2011-02-16 | Univ Indiana Res & Tech Corp | Profarmaco de peptido de la superfamilia de glucagon basados en amida |
KR20120087875A (ko) | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
AU2012213435B2 (en) * | 2011-02-02 | 2017-03-30 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
RU2014101697A (ru) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
EP2729493B1 (en) | 2011-07-04 | 2020-06-10 | IP2IPO Innovations Limited | Novel compounds and their effects on feeding behaviour |
JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
CN104662038B (zh) * | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
BR112015014510A2 (pt) | 2012-12-21 | 2017-11-21 | Sanofi Sa | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais |
CA2916222C (en) | 2013-06-28 | 2021-05-18 | Amgen Inc. | Stable liquid formulation of amg 416 (etelcalcetide) |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
MX2017007699A (es) | 2014-12-12 | 2017-09-18 | Sanofi Aventis Deutschland | Formulacion de proporcion fija de insulina glargina/lixisenatida. |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
WO2020127476A1 (en) | 2018-12-19 | 2020-06-25 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
WO2021123228A1 (en) | 2019-12-18 | 2021-06-24 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
WO2022157747A2 (en) * | 2021-01-25 | 2022-07-28 | Mylan Ireland Limited | Pharmaceutical peptide compositions and methods of preparation thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001525371A (ja) * | 1997-12-05 | 2001-12-11 | イーライ・リリー・アンド・カンパニー | Glp−1製剤 |
US6380357B2 (en) * | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
ES2249933T3 (es) * | 1998-12-22 | 2006-04-01 | Eli Lilly And Company | Formulacion autoestable de peptido 1 tipo glucagon. |
US7199217B2 (en) * | 2000-12-13 | 2007-04-03 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
US6573237B2 (en) * | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
DK1412384T3 (da) * | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
MXPA04001560A (es) * | 2001-08-28 | 2004-05-17 | Lilly Co Eli | Premezclas de glp-1 e insulina basal. |
-
2004
- 2004-06-03 KR KR1020057023115A patent/KR101293507B1/ko active IP Right Grant
- 2004-06-03 PL PL04735870T patent/PL1633390T3/pl unknown
- 2004-06-03 AU AU2004243531A patent/AU2004243531B2/en not_active Expired
- 2004-06-03 CA CA002527743A patent/CA2527743A1/en not_active Abandoned
- 2004-06-03 EP EP04735870A patent/EP1633390B1/en not_active Expired - Lifetime
- 2004-06-03 MX MXPA05013048A patent/MXPA05013048A/es active IP Right Grant
- 2004-06-03 WO PCT/DK2004/000380 patent/WO2004105781A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1633390B1 (en) | 2012-01-18 |
AU2004243531A1 (en) | 2004-12-09 |
AU2004243531B2 (en) | 2009-11-05 |
WO2004105781A2 (en) | 2004-12-09 |
EP1633390A2 (en) | 2006-03-15 |
WO2004105781A3 (en) | 2005-03-17 |
KR20060017531A (ko) | 2006-02-23 |
PL1633390T3 (pl) | 2012-06-29 |
CA2527743A1 (en) | 2004-12-09 |
KR101293507B1 (ko) | 2013-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05013048A (es) | Composiciones peptodicas farmaceuticas estabilizadas. | |
EP2292254A3 (en) | Stabilized pharmaceutical peptide compositions | |
EP2292253A3 (en) | Stabilized pharmaceutical peptide compositions | |
WO2007133637A3 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
MXPA05006568A (es) | Compuestos de pirazol aciclico para la inhibicion de proteina cinasa-2 activada por proteina cinasa activada por mitogenos. | |
WO2006058539A3 (en) | Growth hormone secretagogue receptor 1a ligands | |
TW200505837A (en) | Novel compounds | |
UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
TW200519075A (en) | Novel compounds | |
MX2009003305A (es) | Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso. | |
WO2008064018A8 (en) | Thienopyrimidinones for treatment of inflammatory disorders and cancers | |
WO2005115470A3 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS | |
WO2008064351A3 (en) | (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs | |
WO2006099943A8 (de) | Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
TW200628473A (en) | Novel heterocycles | |
WO2007112000A3 (en) | Treatment of pain | |
MY138708A (en) | Biaryloxymethylarenecarboxylic acids | |
DE60110054D1 (en) | Cardioprotektive phosphonate | |
WO2007100758A3 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
EP2215054B8 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
WO2006113718A3 (en) | Compositions for the treatment of neoplasms | |
WO2006099410A3 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
WO2005055939A3 (en) | Vinca derivatives | |
WO2004073615A8 (en) | Deazaflavin compounds and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |